Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
Is a |
Product containing gramicidin (medicinal product) |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
Is a |
Product containing neomycin (medicinal product) |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
Is a |
øjendråber indeholdende polymyxin B |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
Is a |
kombinationspræparater med neomycin |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
Is a |
neomycin til topikal anvendelse |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Polymyxin B (substance) |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
neomycin til topikal anvendelse |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Gramicidin (substance) |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
Is a |
gramicidin + neomycinsulfat + polymyxin B-sulfat |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Polymyxin B sulfate |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Antiinfektiøst middel til huden |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Neomycin sulfate |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Baktericid |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Local anti-infective |
false |
Inferred relationship |
Some |
|
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
Has manufactured dose form |
Ocular dose form (dose form) |
false |
Inferred relationship |
Some |
|
|